Last updated: March 20, 2026
What Is NDC 00169-4425?
NDC 00169-4425 refers to a generic formulation of duloxetine, marketed primarily under the brand name Cymbalta. It is an SNRI (serotonin-norepinephrine reuptake inhibitor) indicated for major depressive disorder, generalized anxiety disorder, fibromyalgia, and diabetic peripheral neuropathy.
Market Overview
Market Size and Penetration
The global antidepressant market was valued at approximately USD 14.7 billion in 2022, with duloxetine accounting for a significant share due to its expanded indications. The drug's approval date was March 2004, with its patent expired in 2013, leading to increased generic entry.
In the United States, duloxetine prescriptions reached approximately 15 million annually (IQVIA, 2022). Generics hold over 80% of prescription volume, with branded Cymbalta maintaining a smaller share.
Competitive Landscape
Key competitors include:
- Escitalopram (Lexapro)
- Sertraline (Zoloft)
- Venlafaxine (Effexor)
- Other generic SNRI options
Generic duloxetine products are manufactured by multiple firms, including Teva, Sun Pharma, and Mylan.
Regulatory Environment
The original patent expiration in 2013 opened the market for generics. Currently, no active patent protections limit manufacturing of NDC 00169-4425.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 30-day supply |
Market Share of Generics |
| 2018 |
USD 350 |
60% |
| 2020 |
USD 250 |
75% |
| 2022 |
USD 180 |
85% |
The significant drop from USD 350 to USD 180 signifies increased generic competition and price erosion.
Price Drivers
- Number of Manufacturers: Increased competition reduces prices.
- Formulation Complexity: Simple oral capsules keep manufacturing costs low.
- Payer Negotiations: Managed care organizations negotiate rebates, affecting net prices.
Future Price Projections
Over the next 3 years, prices are expected to stabilize around USD 150–USD 180 per 30-day supply due to market saturation. No major generic entrants are forecasted to significantly alter the landscape.
Market Entry and Expansion Opportunities
- New Formulations: Extended-release versions could command premium prices.
- Indication Expansion: Approvals for new psychiatric or neurological conditions could increase demand.
- Export Markets: Emerging markets lack rigorous price controls, offering higher margins.
Pricing Comparison with Analogous Drugs
| Drug |
Therapeutic Indications |
Brand Price (USD) |
Generic Price Range (USD) |
| Duloxetine |
Depression, GAD, FMS, PN |
180 |
150–200 |
| Venlafaxine |
Depression, GAD |
200 |
120–180 |
| Sertraline |
Depression |
160 |
80–120 |
Duloxetine's price remains higher than some SSRIs but lower than other SNRIs.
Key Takeaways
- The global market for duloxetine is mature, with extensive generic competition driven by patent expiry in 2013.
- Prices have declined steadily from USD 350 to USD 180 per 30-day supply, stabilizing with limited upside.
- Market penetration is high in the US, with continued growth potential in emerging markets.
- Opportunities exist in new formulations and indications but face competition from established therapies.
- Price projections remain around USD 150–USD 180 over the next three years unless significant patent or regulatory changes occur.
FAQs
1. Will the price of NDC 00169-4425 decrease further?
It is unlikely; prices have stabilized due to high generic competition. Further decreases are limited unless new market entrants emerge or supply-side factors change.
2. Are there patent protections preventing new generics?
No, the original patent expired in 2013. However, secondary patents or litigation could impact market entry temporarily.
3. How does the price of duloxetine compare internationally?
Prices vary globally. In Europe, generic versions are available at approximately USD 50–USD 100 per month. In emerging markets, prices are often below USD 50.
4. What are the key factors influencing duloxetine's market share?
Efficacy, safety profile, prescribing habits, pharmaceutical marketing, and insurance coverage.
5. Could new indications increase the drug's value?
Yes, regulatory approval for additional psychiatric or neurological conditions could expand the market and support higher prices.
Sources:
[1] IQVIA. (2022). Prescription Data Report.
[2] U.S. Food and Drug Administration. (2013). Patent and Exclusivity Data.
[3] Expert Market Reports. (2022). Global Antidepressant Market Analysis.
